Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon towards the development of tesamorelin for the potential treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in people living with HIV (Study).
The MGH, through Dr. Steven Grinspoon, who is chief of the hospital’s Metabolism Unit, has agreed to assist Theratechnologies in connection with the Study design, selection of optimal patient population, dosing, Study duration and other safety matters and to participate, if need be, in regulatory meetings with the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA). In consideration, Theratechnologies has agreed to make certain milestone payments related to the development of tesamorelin for the treatment of NAFLD/NASH and royalty payments on all sales of EGRIFTA® (tesamorelin for injection), above a certain threshold amount, upon approval by the FDA or the EMA (the first to occur) of an expanded label of tesamorelin for the treatment of NAFLD or NASH in the HIV patient population. In addition, Dr. Grinspoon will become a member of Theratechnologies’ scientific committee. In such a role, Dr. Grinspoon will provide guidance about current developments in the HIV patient population, potential treatments, and the possible development of tesamorelin for treatment of additional diseases. Dr. Grinspoon will also provide advice to Theratechnologies in connection with the Study.
